Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) reported Q2 2017 earnings this Afternoon, coming in at $0.11 per share, beating Wall Street’s estimates of $0.07 per Share. Revenue for the quarter came in at $65.20 million beating analyst estimates of $63.40 million
Analyst Coverage For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
These are 1 Hold Rating, 5 Buy Ratings .
The current consensus rating for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is Buy (Score: 2.83) with a consensus target price of $20.17 , a potential (29.77% upside)Recent Insider Trading for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
- On 6/9/2017 Richard K Prins, Director, sold 10,000 with an average share price of $17.07 per share and the total transaction amounting to $170,700.00.
- On 6/1/2017 Michael A Zasloff, Director, sold 15,000 with an average share price of $17.01 per share and the total transaction amounting to $255,150.00.
- On 5/31/2017 Jason B Shandell, Director, sold 11,482 with an average share price of $16.92 per share and the total transaction amounting to $194,275.44.
- On 5/11/2017 Richard K Prins, Director, sold 7,500 with an average share price of $15.43 per share and the total transaction amounting to $115,725.00.
- On 1/3/2017 Floyd F Petersen, Director, sold 400 with an average share price of $18.61 per share and the total transaction amounting to $7,444.00.
- On 12/15/2016 Diane G Gerst, EVP, sold 2,940 with an average share price of $20.51 per share and the total transaction amounting to $60,299.40.
Recent Trading for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares of Amphastar Pharmaceuticals, Inc. closed the previous trading session at 15.54 down -0.10 -0.64% with 249,513 shares trading hands.